Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 79
Filter
1.
Acta Med Indones ; 53(1): 105-107, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33818413

ABSTRACT

Acute bacterial skin and skin-structure infections (ABSSSI) is defined in 2013 by the US Food and Drug Administration as a bacterial cellulitis/erysipelas, major skin abscesses, and wound infections. The Infectious Diseases Society of America (IDSA) in 2014 classifies skin and soft-tissue infection (SSTI) as either non-purulent (which includes cellulitis, erysipelas, and necrotizing infection) or purulent (including furuncle, carbuncle, and abscess). Among hospitalized patients with SSTI, healthcare-associated infections account for 73.5% of all cases. Notably, skin and skin-structure infections caused by Pseudomonas aeruginosa, a common hospital pathogen, was reported to cause higher total cost and longer hospital length of stay compared to non-P. aeruginosa cases, despite causing only approximately 5.7% of all healthcare-associated SSTIs. Infection with P. aeruginosa should always be considered in non-healing skin infections in patients with prolonged hospitalization and antibiotic exposure. Tissue culture, preferably taken by surgical debridement, should be promptly performed; and when hospital-infection is suspected, appropriate antibiotics should be started along with removal of all devitalized tissue and to promote skin and soft tissue healing. Expedited discharge should be considered when possible, with adequate antibiotic treatment and follow up for definitive wound treatment.


Subject(s)
COVID-19/complications , Debridement/methods , Iatrogenic Disease , Linezolid/administration & dosage , Skin Diseases, Infectious , Anti-Bacterial Agents/administration & dosage , COVID-19/diagnosis , COVID-19/physiopathology , Female , Hospitalization , Humans , Middle Aged , SARS-CoV-2/isolation & purification , Skin/microbiology , Skin/pathology , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/etiology , Skin Diseases, Infectious/physiopathology , Skin Diseases, Infectious/therapy , Treatment Outcome
2.
Clin Exp Allergy ; 51(3): 382-392, 2021 03.
Article in English | MEDLINE | ID: mdl-33394511

ABSTRACT

Atopic dermatitis (AD) is a chronic relapsing inflammatory cutaneous disease that is often associated with other atopic symptoms, such as food allergy, allergic rhinitis and asthma, leading to significant morbidity and healthcare costs. The pathogenesis of AD is complicated and multifactorial. Although the aetiology of AD remains incompletely understood, recent studies have provided further insight into AD pathophysiology, demonstrating that the interaction among genetic predisposition, immune dysfunction and environmental provocation factors contributes to its development. However, the increasing prevalence of AD suggests that environmental factors such as irritation and cutaneous infection play a crucial role in triggering and/or aggravating the disease. Of note, AD skin is susceptible to bacterial, fungal and viral infections, and microorganisms may colonize the skin and aggravate AD symptoms. Overall, understanding the mechanisms by which these risk factors affect the cutaneous immunity of patients with AD is of great importance for developing a precision medicine approach for treatment. This review summarizes recent developments in exogenous factors involved in the pathogenesis of AD, with special emphasis on irritants and microbial infections.


Subject(s)
Dermatitis, Atopic/physiopathology , Irritants/adverse effects , Skin Diseases, Infectious/microbiology , Skin/microbiology , Dermatitis, Atopic/immunology , Dermatitis, Atopic/microbiology , Humans , Kaposi Varicelliform Eruption/immunology , Kaposi Varicelliform Eruption/physiopathology , Microbiota , Molluscum Contagiosum/immunology , Molluscum Contagiosum/physiopathology , Skin Diseases, Infectious/immunology , Skin Diseases, Infectious/physiopathology
3.
PLoS One ; 15(7): e0235350, 2020.
Article in English | MEDLINE | ID: mdl-32663203

ABSTRACT

BACKGROUND: Skin and soft tissue infections (SSTI) are a common but preventable cause of morbidity and mortality among people who inject drugs (PWID). They can be severe, and hospitalisations of PWID with SSTI are rising. The most common SSTI presentations are abscesses and cellulitis. METHODS: We used data from Care & Prevent, a cross-sectional community survey of PWID in London. We reported the lifetime prevalence of SSTI, severity of infections, key risk factors, and associated sequelae. Pictorial questions were used to assess SSTI severity. RESULTS: We recruited 455 PWID. SSTI lifetime prevalence was high: 64% reported an abscess and/or cellulitis. Over one-third (37%) reported a severe infection, 137 (47%) reported hospitalisation. SSTIrisk factors were: aged 35+ years, injecting once or more times a day, subcutaneous or intra-muscular injections, and making four or more attempts to achieve an injection. Those who reported having other health conditions were at higher odds of having an abscess or cellulitis, with risk tending to increase with number of reported conditions. Half (46%) employed self-care for their worst SSTI, and 43% waited for ten or more days before seeking medical care or not seeking medical care at all. CONCLUSIONS: Abscess and cellulitis are very common among PWID in London. We corroborate findings indicating SSTIs are associated with risks, e.g. venous access problems, as well as other co-morbid conditions: septicaemia, endocarditis, DVT, and kidney disease. These co-morbidities may impact SSTIs severity and outcomes. Delayed healthcare seeking potentially exacerbates infection severity, which in turn increases poorer health outcomes and complications.


Subject(s)
Abscess/epidemiology , Cellulitis/epidemiology , Skin Diseases, Infectious/epidemiology , Substance Abuse, Intravenous/epidemiology , Abscess/complications , Abscess/physiopathology , Adult , Cellulitis/complications , Cellulitis/physiopathology , Female , Humans , London/epidemiology , Male , Middle Aged , Outcome Assessment, Health Care , Patient Acceptance of Health Care , Prevalence , Risk Factors , Sepsis/complications , Sepsis/epidemiology , Sepsis/physiopathology , Skin Diseases, Infectious/complications , Skin Diseases, Infectious/physiopathology , Substance Abuse, Intravenous/complications , Substance Abuse, Intravenous/physiopathology , United Kingdom/epidemiology
4.
Medicine (Baltimore) ; 99(12): e19516, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32195953

ABSTRACT

Established conventional treatments for postherpetic neuralgia (PHN) and postherpetic itch (PHI) are difficult and often disappointing. In this study, the authors investigated the effect and mechanisms of extracorporeal shockwave therapy (ESWT) on pain and itch associated with PHN and PHI.Thirteen patients, 50 to 80 years of age, with symptoms associated with PHN or PHI (duration of persistent pain >3 months) and complaints of pain or itch rated >4 on a numerical rating scale (NRS), were included. ESWT was administered using a shockwave device (Piezo Shockwave, Richard Wolf GmbH, Knittlingen, Germany) to skin areas affected by pain or itch. An energy flux density of 0.09 to 0.16 mJ/mm at a frequency of 5 Hz and 2000 impulses was administered at 3-day intervals for 6 sessions. The NRS, 5D-Itch Scale, and Patients Global Impression of Change (PGIC) scale were used to evaluate the efficacy of ESWT.NRS scores of pain and itch and 5D-Itch Scale scores decreased significantly compared with before treatment and at the end of the treatment sessions (P < .0001, P = .001, P = .0002, respectively). There was a statistically significant difference between PGIC scores, which were checked every 2 sessions (P < .0001).ESWT is a noninvasive modality that significantly reduced PHN-associated pain and itch.


Subject(s)
Extracorporeal Shockwave Therapy/methods , Neuralgia, Postherpetic/therapy , Pruritus/therapy , Skin Diseases, Infectious/therapy , Aged , Aged, 80 and over , Extracorporeal Shockwave Therapy/instrumentation , Female , Herpesvirus 3, Human/isolation & purification , Humans , Male , Middle Aged , Neuralgia, Postherpetic/physiopathology , Neuralgia, Postherpetic/virology , Pruritus/etiology , Republic of Korea/epidemiology , Skin Diseases, Infectious/physiopathology , Skin Diseases, Infectious/virology , Treatment Outcome
5.
Am J Emerg Med ; 37(1): 48-52, 2019 01.
Article in English | MEDLINE | ID: mdl-29716798

ABSTRACT

PURPOSE: The purpose was to determine significant predictors of treatment failure of skin and soft tissue infections (SSTI) in the inpatient and outpatient setting. METHODS: A retrospective chart review of patients treated between January 1, 2005 to July 1, 2016 with ICD-9 or ICD-10 code of cellulitis or abscess. The primary outcome was failure defined as an additional prescription or subsequent hospital admission within 30 days of treatment. Risk factors for failure were identified through multivariate logistic regression. RESULTS: A total of 541 patients were included. Seventeen percent failed treatment. In the outpatient group, 24% failed treatment compared to 9% for inpatients. Overweight/obesity (body mass index (BMI) > 25 kg/m2) was identified in 80%, with 15% having a BMI >40 kg/m2. BMI, heart failure, and outpatient treatment were determined to be significant predictors of failure. The unit odds ratio for failure with BMI was 1.04 (95% [Cl] = 1.01 to 1.1, p = 0.0042). Heart failure increased odds by 2.48 (95% [Cl] = 1.3 to 4.7, p = 0.0056). Outpatients were more likely to fail with an odds ratio of 3.36. CONCLUSION: Patients with an elevated BMI and heart failure were found to have increased odds of failure with treatment for SSTIs. However, inpatients had considerably less risk of failure than outpatients. These risk factors are important to note when making the decision whether to admit a patient who presents with SSTI in the emergency department. Thoughtful strategies are needed with this at-risk population to prevent subsequent admission.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Skin Diseases, Infectious/physiopathology , Soft Tissue Infections/physiopathology , Adult , Aged , Aged, 80 and over , Body Mass Index , Comorbidity , Emergency Service, Hospital , Female , Humans , Logistic Models , Male , Middle Aged , Retrospective Studies , Risk Assessment , Skin Diseases, Infectious/drug therapy , Skin Diseases, Infectious/epidemiology , Soft Tissue Infections/drug therapy , Soft Tissue Infections/epidemiology , Treatment Failure , United States/epidemiology , Young Adult
6.
Cutis ; 101(3): 187-190, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29718024

ABSTRACT

The Ixodes tick is an important arthropod vector in the transmission of human disease. This 3-part review highlights the biology of the Ixodes tick and manifestations of related diseases. Part 1 addresses the Ixodes tick biology and life cycle; local reactions; and Lyme disease, the most prevalent of associated diseases. Part 2 will address human granulocytic anaplasmosis, babesiosis, Powassan virus infection, Borrelia miyamotoi disease, tick-borne encephalitis, and tick paralysis. Part 3 will address coinfection with multiple pathogens as well as methods of tick-bite prevention and tick removal.


Subject(s)
Babesiosis/physiopathology , Ixodes/physiology , Lyme Disease/physiopathology , Skin Diseases, Infectious/physiopathology , Tick Infestations/physiopathology , Animals , Babesiosis/parasitology , Babesiosis/therapy , Humans , Ixodes/growth & development , Ixodes/parasitology , Life Cycle Stages , Lyme Disease/parasitology , Lyme Disease/therapy , Parasitic Diseases/parasitology , Parasitic Diseases/physiopathology , Parasitic Diseases/therapy , Tick Bites/physiopathology , Tick Bites/therapy , Tick Infestations/therapy
8.
West J Emerg Med ; 18(3): 398-402, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28435490

ABSTRACT

INTRODUCTION: The objectives of this study were to determine the prevalence of fever in adult ED patients with skin and soft tissue infections (SSTI) and to determine which, if any, physical exam, radiograph and laboratory test findings were associated with fever. METHODS: We conducted a prospective, observational study at an urban county trauma center of adults who presented to the ED for evaluation of suspected SSTI. ED providers measured area of erythema and induration using a tape measure, and completed data sheets indicating comorbid conditions and the presence or absence of physical exam findings. Fever was defined as any recorded temperature ≥ 38°C during the first six hours of ED evaluation. RESULTS: Of the 734 patients enrolled, 96 (13.1%) had fever. Physical and laboratory exam findings associated with the presence of a fever in multivariable logistic regression were the area of erythema, particularly the largest quartile of area of erythema, 144 - 5,000 cm2, (odd ratio [OR] = 2.9; 95% confidence interval [CI] [1.6 - 5.2]) and leukocytosis (OR = 4.4, 95% CI [2.7 - 7.0]). Bullae, necrosis, streaks, adenopathy, and bone involvement on imaging were not associated with fever. CONCLUSION: Fever is uncommon in patients presenting to the ED for evaluation of suspected SSTI. Area of erythema and leukocytosis were associated with fever and should be considered in future decision rules for the evaluation and treatment of SSTI.


Subject(s)
Emergency Service, Hospital , Fever/diagnosis , Hospitalization/statistics & numerical data , Skin Diseases, Infectious/diagnosis , Soft Tissue Infections/diagnosis , Adolescent , Adult , Erythema , Female , Fever/physiopathology , Fever/therapy , Humans , Logistic Models , Male , Physical Examination , Practice Guidelines as Topic , Prospective Studies , Skin Diseases, Infectious/physiopathology , Skin Diseases, Infectious/therapy , Soft Tissue Infections/physiopathology , Soft Tissue Infections/therapy , United States
9.
Arkh Patol ; 79(1): 52-55, 2017.
Article in Russian | MEDLINE | ID: mdl-28295008

ABSTRACT

The paper describes a case of a rare opportunistic infection, such as skin lesion caused by achlorophyllic unicellular algae of the genus Prototheca. It provides a detailed pathologic description of the foci of cutaneous protothecosis, such as pandermal inflammatory infiltrate, granulomas, pseudoepitheliomatous hyperplasia, and intraepidermal abscesses. Criteria for pathogen detection in histological sections are given.


Subject(s)
Prototheca/isolation & purification , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/physiopathology , Aged , Female , Humans , Prototheca/pathogenicity , Skin Diseases, Infectious/microbiology
10.
FP Essent ; 453: 26-32, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28196318

ABSTRACT

Skin infections account for a significant subset of dermatologic conditions of childhood. Common cutaneous viral infections in children include warts, molluscum contagiosum, hand-foot-and-mouth disease, and herpes simplex. Although viral infections are self-limited and often only mildly symptomatic, they can cause anxiety, embarrassment, and health care use. Recognition of their common and atypical presentations is necessary to differentiate them from other skin conditions of similar morphology. Impetigo, cellulitis, and abscess comprise the majority of childhood bacterial skin infections and are treated with topical or systemic antibiotics that cover group A Streptococcus and Staphylococcus aureus. Common fungal dermatologic infections in children are oral and genital candidiasis, tinea capitis, and tinea corporis. Management consists of topical and systemic antifungals, including nystatin, triazoles, terbinafine, griseofulvin, and imidazoles. Scabies is the most common parasitic skin infection among children and is managed with topical permethrin. Although serious illness is not common among children returning from international travel, patients presenting with fever and rash, especially petechial or hemorrhagic lesions, require thorough evaluation. Of the numerous reportable conditions that present with childhood rash, tick-borne illnesses, measles, rubella, and varicella are the most common.


Subject(s)
Family Practice , Skin Diseases, Infectious/drug therapy , Skin Diseases, Infectious/physiopathology , Child , Dermatomycoses/drug therapy , Dermatomycoses/physiopathology , Disease Notification/standards , Humans , Skin Diseases, Bacterial/drug therapy , Skin Diseases, Bacterial/physiopathology , Skin Diseases, Infectious/diagnostic imaging , Skin Diseases, Parasitic/drug therapy , Skin Diseases, Parasitic/physiopathology , Skin Diseases, Viral/drug therapy , Skin Diseases, Viral/physiopathology
11.
Br J Dermatol ; 177(4): 914-923, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28129674

ABSTRACT

Mutations in the BRAF proto-oncogene occur in the majority of cutaneous melanomas. The commonly detected valine (V) to glutamate (E) mutation (V600E) is known to drive melanomagenesis and has thus been the target of two highly selective chemotherapeutic agents: vemurafenib and dabrafenib. While BRAF inhibitor therapy has revolutionized the treatment of metastatic melanoma, unanticipated cutaneous toxicities, including the development of cutaneous squamous cell carcinomas (cSCCs), are frequently reported and hinder therapeutic durability. However, the mechanisms by which BRAF inhibitors induce cutaneous neoplasms are poorly understood, thus posing a challenge for specific therapies. In this review, we summarize the clinical and molecular profiles of BRAF inhibitor-associated cSCCs, with a focus on factors that may contribute to disease pathogenesis. In particular, we discuss the emerging evidence pointing towards viral involvement in BRAF inhibitor-induced cutaneous neoplasms and offer new perspectives on future therapeutic interventions. Continued clinical and mechanistic studies along this line will not only allow for better understanding of the pathogenic progression of BRAF inhibitor-induced cSCCs, but will also lead to development of new therapeutic and preventative options for patients receiving targeted cancer therapy.


Subject(s)
Antineoplastic Agents/adverse effects , Carcinoma, Squamous Cell/chemically induced , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Skin Neoplasms/chemically induced , Aged , Carcinoma, Squamous Cell/prevention & control , Humans , Middle Aged , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Molecular Targeted Therapy , Papillomavirus Infections/physiopathology , Polyomavirus Infections/physiopathology , Proto-Oncogene Mas , Skin Diseases, Infectious/physiopathology , Skin Neoplasms/prevention & control , Tumor Virus Infections/physiopathology
12.
S Afr Med J ; 106(9): 888-90, 2016 Aug 03.
Article in English | MEDLINE | ID: mdl-27601113

ABSTRACT

A 1-week-old infant was brought to a regional hospital with a history of recurrent seizures following lower abdominal septic skin infection. She was found to have neonatal tetanus, and a spatula test was positive. The tetanus infection was associated with a superficial skin infection, common in neonates. Treatment included sedatives (diazepam, chlorpromazine, phenobarbitone and morphine), muscle relaxants, antibiotics and ventilation in the neonatal intensive care unit. Intrathecal and intramuscular immunoglobulin were given, and the wound was treated. The infant recovered, with no seizures by the 16th day from admission, and was off the ventilator by the 18th day. This was shorter than the usual 3 - 4 weeks for neonates with tetanus at the hospital. The question arises whether tetanus immunisation should be considered in infants with skin infections, which frequently occur in the neonatal period.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anticonvulsants/administration & dosage , Delayed Diagnosis , Hypnotics and Sedatives/administration & dosage , Skin Diseases, Infectious/complications , Skin/pathology , Tetanus Antitoxin/administration & dosage , Tetanus , Abdominal Wall , Debridement/methods , Delayed Diagnosis/adverse effects , Delayed Diagnosis/prevention & control , Female , Humans , Immunologic Factors/administration & dosage , Infant, Newborn , Necrosis , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/physiopathology , Skin Diseases, Infectious/therapy , Tetanus/diagnosis , Tetanus/etiology , Tetanus/physiopathology , Tetanus/therapy , Treatment Outcome
13.
Intern Emerg Med ; 11(5): 637-48, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27084183

ABSTRACT

Skin and soft tissue infections (SSTIs) are a common cause of hospital admission among elderly patients, and traditionally have been divided into complicated and uncomplicated SSTIs. In 2010, the FDA provided a new classification of these infections, and a new category of disease, named acute bacterial skin and skin structure infections (ABSSSIs), has been proposed as an independent clinical entity. ABSSSIs include three entities: cellulitis and erysipelas, wound infections, and major cutaneous abscesses This paper revises the epidemiology of SSTIs and ABSSSIs with regard to etiologies, diagnostic techniques, and clinical presentation in the hospital settings. Particular attention is owed to frail patients with multiple comorbidities and underlying significant disease states, hospitalized on internal medicine wards or residing in nursing homes, who appear to be at increased risk of infection due to multi-drug resistant pathogens and treatment failures. Management of ABSSSIs and SSTIs, including evaluation of the hemodynamic state, surgical intervention and treatment with appropriate antibiotic therapy are extensively discussed.


Subject(s)
Anti-Bacterial Agents/pharmacology , Internal Medicine/methods , Skin Diseases, Infectious/drug therapy , Soft Tissue Infections/drug therapy , Aged , Aged, 80 and over , Carbapenems/adverse effects , Carbapenems/pharmacokinetics , Cephalosporins/adverse effects , Cephalosporins/pharmacokinetics , Cephalosporins/therapeutic use , Daptomycin/pharmacology , Daptomycin/therapeutic use , Female , Fluoroquinolones/adverse effects , Fluoroquinolones/pharmacokinetics , Glycopeptides/pharmacology , Glycopeptides/therapeutic use , Hospitalization , Humans , Iatrogenic Disease , Internal Medicine/standards , Linezolid/pharmacology , Linezolid/therapeutic use , Lipoglycopeptides , Male , Minocycline/analogs & derivatives , Minocycline/pharmacology , Minocycline/therapeutic use , Oxazolidinones/pharmacology , Oxazolidinones/therapeutic use , Skin Diseases, Infectious/physiopathology , Soft Tissue Infections/physiopathology , Teicoplanin/analogs & derivatives , Teicoplanin/pharmacology , Teicoplanin/therapeutic use , Tigecycline , Vancomycin/pharmacology , Vancomycin/therapeutic use , Ceftaroline
15.
Diabetes Metab Res Rev ; 32 Suppl 1: 186-94, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26455509

ABSTRACT

It is known that the relative importance of factors involved in the development of diabetic foot problems can vary in both their presence and severity between patients and lesions. This may be one of the reasons why outcomes seem to vary centre to centre and why some treatments may seem more effective in some people than others. There is a need therefore to classify and describe lesions of the foot in patients with diabetes in a manner that is agreed across all communities but is simple to use in clinical practice. No single system is currently in widespread use, although a number have been published. Not all are well validated outside the system from which they were derived, and it has not always been made clear the clinical purposes to which such classifications should be put to use, whether that be for research, clinical description in routine clinical care or audit. Here the currently published classification systems, their validation in clinical practice, whether they were designed for research, audit or clinical care, and the strengths and weaknesses of each are explored.


Subject(s)
Diabetic Foot/diagnosis , Practice Guidelines as Topic , Cell Hypoxia , Congresses as Topic , Diabetic Angiopathies/complications , Diabetic Angiopathies/diagnosis , Diabetic Angiopathies/microbiology , Diabetic Angiopathies/physiopathology , Diabetic Foot/complications , Diabetic Foot/microbiology , Diabetic Foot/physiopathology , Diabetic Neuropathies/complications , Diabetic Neuropathies/diagnosis , Diabetic Neuropathies/microbiology , Diabetic Neuropathies/physiopathology , Foot/blood supply , Foot/microbiology , Humans , International Agencies , Severity of Illness Index , Skin Diseases, Infectious/complications , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/microbiology , Skin Diseases, Infectious/physiopathology , Soft Tissue Infections/complications , Soft Tissue Infections/diagnosis , Soft Tissue Infections/microbiology , Soft Tissue Infections/physiopathology , Wound Healing
16.
Rev Chilena Infectol ; 32 Suppl 1: S57-71, 2015 Feb.
Article in Spanish | MEDLINE | ID: mdl-25860154

ABSTRACT

The ongoing human immunodeficiency virus (HIV) infection epidemic coupled with more efficacious and available treatments has led to a larger number of patients living with HIV or AIDS. As a result, skin manifestations related to HIV/AIDS or its therapy have become increasingly more common and are reported to occur in as many as 95% of patients. Herein, we review the most common HIV/AIDS related cutaneous pathologies and classify them into inflammatory, HAART-associated, neoplastic, and infectious manifestations. Cutaneous manifestations should be promptly recognized and treated by physicians and health care personnel in order to provide optimal care.


Subject(s)
AIDS-Related Opportunistic Infections/etiology , Acquired Immunodeficiency Syndrome/complications , Skin Diseases, Infectious/etiology , Skin Neoplasms/etiology , AIDS-Related Opportunistic Infections/drug therapy , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/etiology , Angiomatosis, Bacillary/etiology , Anti-Retroviral Agents/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Dermatitis, Seborrheic/etiology , Humans , Psoriasis/etiology , Sarcoma, Kaposi/etiology , Sarcoma, Kaposi/pathology , Skin Diseases, Infectious/physiopathology , Skin Neoplasms/pathology , Syphilis, Cutaneous/etiology
17.
J Am Acad Dermatol ; 72(6): 1066-73, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25840731

ABSTRACT

The umbilicus may be the site of congenital and acquired malformations and may harbor clinical clues to the diagnosis of potentially fatal inherited disorders, primary skin conditions, and a variety of infectious diseases. Both benign and malignant tumors may involve the umbilicus, and some are unique to this site. Finally, cutaneous signs localized to this anatomic location may be found in diverse systemic diseases.


Subject(s)
Congenital Abnormalities/diagnosis , Skin Diseases/congenital , Skin Diseases/pathology , Umbilicus/abnormalities , Adolescent , Adult , Age Factors , Child , Congenital Abnormalities/epidemiology , Female , Humans , Incidence , Infant, Newborn , Male , Middle Aged , Prognosis , Risk Assessment , Sex Factors , Skin Diseases/epidemiology , Skin Diseases, Infectious/epidemiology , Skin Diseases, Infectious/microbiology , Skin Diseases, Infectious/physiopathology , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Skin Neoplasms/physiopathology , Umbilicus/physiopathology
18.
Rev. chil. infectol ; 32(supl.1): 57-71, feb. 2015. ilus, tab
Article in Spanish | LILACS | ID: lil-742526

ABSTRACT

The ongoing human immunodeficiency virus (HIV) infection epidemic coupled with more efficacious and available treatments has led to a larger number of patients living with HIV or AIDS. As a result, skin manifestations related to HIV/AIDS or its therapy have become increasingly more common and are reported to occur in as many as 95% of patients. Herein, we review the most common HIV/AIDS related cutaneous pathologies and classify them into inflammatory, HAART-associated, neoplastic, and infectious manifestations. Cutaneous manifestations should be promptly recognized and treated by physicians and health care personnel in order to provide optimal care.


La epidemia del virus de la inmunodeficiencia humana (VIH) sumado al mayor acceso a terapias antiretrovirales (TARV) han llevado a un aumento del número y la sobrevida de pacientes que viven con esta infección crónica. Se estima que hasta 95% de los pacientes con infección por VIH/SIDA presentarán alguna manifestación cutánea, por lo cual, debemos conocerlas. En la presente revisión se estudiarán las manifestaciones cutáneas de la infección por el VIH/SIDA clasificadas como: manifestaciones inflamatorias, manifestaciones asociadas a la TARV, manifestaciones neoplásicas y manifestaciones infecciosas asociadas a infección por VIH/SIDA (bacterianas, virales, fúngicas y parasitarias). Estas manifestaciones deben ser reconocidas por los médicos y el personal de salud a cargo del tratamiento y control de los pacientes con esta patología crónica.


Subject(s)
Humans , AIDS-Related Opportunistic Infections/etiology , Acquired Immunodeficiency Syndrome/complications , Skin Diseases, Infectious/etiology , Skin Neoplasms/etiology , AIDS-Related Opportunistic Infections/drug therapy , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/etiology , Angiomatosis, Bacillary/etiology , Anti-Retroviral Agents/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Dermatitis, Seborrheic/etiology , Psoriasis/etiology , Sarcoma, Kaposi/etiology , Sarcoma, Kaposi/pathology , Skin Diseases, Infectious/physiopathology , Skin Neoplasms/pathology , Syphilis, Cutaneous/etiology
19.
J Am Acad Dermatol ; 72(1): 1-19; quiz 19-20, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25497917

ABSTRACT

Epstein-Barr virus (EBV) is a ubiquitous virus that has been implicated in a wide range of human diseases, many of which have mucocutaneous manifestations. As a member of the herpesviridae family, EBV causes lifelong infection by establishing latency in B lymphocytes. An intact immune response is critical in preventing progression of EBV disease, and the clinical manifestations of infection are dependent on the intricate relationship between virus and host immune system. This review provides a comprehensive overview of the epidemiology, pathophysiology, and diagnostic testing in EBV infection. In part I of this continuing medical education article, the mucocutaneous manifestations of EBV infection are reviewed with an emphasis on pathophysiology and management.


Subject(s)
Epstein-Barr Virus Infections/complications , Skin Diseases, Infectious/virology , Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Infections/physiopathology , Humans , Hydroa Vacciniforme/virology , Infectious Mononucleosis/virology , Leukoplakia, Hairy/virology , Mucous Membrane , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/physiopathology
20.
Actas dermo-sifiliogr. (Ed. impr.) ; 105(supl.1): 34-40, oct. 2014. tab
Article in English | IBECS | ID: ibc-136175

ABSTRACT

IL-17 immunity has been shown to be essential for mucocutaneous protection against Candida albicans in mice and humans. However, mice with defective IL-17 immunity display broader susceptibility, as they are also prone to infections with diverse infectious agents at various sites. Humans with genetic defects affecting their IL-17 immunity usually suffer from chronic mucocutaneous candidiasis (CMC): recurrent or persistent infections of the skin, nails, and mucosae with C. albicans, with or without other clinical signs. Most patients with autosomal dominant (AD) hyper-IgE syndrome (HIES) due to STAT3 deficiency or AD STAT1 gain-of-function display impaired IL-17-producing T-cell development, and CMC is one of their principal clinical manifestations. Similarly, patients with autosomal recessive (AR) autoimmune polyendocrine syndrome type 1 (APS-1) caused by AIRE deficiency have high levels of neutralizing autoantibodies against IL-17A, IL-17F and/or IL-22 and present CMC as their only infectious disease. Finally, CMC is the main clinical phenotype observed in patients with inborn errors specifically affecting IL-17 immunity. Indeed, patients with AD IL-17F deficiency or AR IL-17RA or ACT1 deficiency display CMC and, to a lesser extent, superficial staphylococcal diseases. Candida infection was recently reported in psoriasis patients treated with anti-IL-17A antibodies. Careful monitoring for CMC is thus important during anti-IL-17 treatment


Se ha demostrado que la inmunidad IL-17 es esencial para la protección mucocutánea contra la Candida albicans en ratones y humanos. Independientemente, los ratones con inmunidad IL-17 defectuosa muestran una susceptibilidad más amplia, de modo que también son propensos a infecciones por diversos agentes infecciosos en varios lugares. Los humanos con defectos genéticos que afectan su inmunidad IL-17 habitualmente padecen candidiasis mucocutánea crónica (CMC): infecciones cutáneas recurrentes o persistentes de uñas y mucosas por C. albicans, con o sin otros signos clínicos. Muchos pacientes con síndrome de hiper IgE autosómico dominante (AD-HIES) debido a deficiencia STAT3 o a aumento de función AD STAT1 muestran un desarrollo dañado de células T productoras de IL-17 y la CMC es una de sus principales manifestaciones. De igual manera, los pacientes con síndrome poliendocrino autoinmune tipo 1 recesivo autosómico (AR-APS-1) causado por deficiencia de AIRE (regulador autoinmune) presentan altos niveles de anticuerpos neutralizantes contra IL-17A, IL-17F y/o IL-22 y padecen CMC como su única enfermedad infecciosa. Finalmente, la CMC es el principal fenotipo clínico observado en pacientes con errores innatos, específicamente aquellos que afectan la inmunidad IL-17. De hecho, los pacientes con deficiencia AD IL-17F o deficiencia IL-17RA o ACT1 presentan CMC y, en menor medida, enfermedades estafilocócicas superficiales. Se ha informado recientemente CMC en pacientes tratados con anticuerpos anti-IL-17A. Es importante el control cuidadoso de la CMC en estos pacientes durante el tratamiento con anti-IL-17ª


Subject(s)
Humans , Male , Female , Infections/immunology , Infections/therapy , Interleukin-17/therapeutic use , Candidiasis/therapy , Candidiasis, Chronic Mucocutaneous/therapy , Skin Diseases, Infectious/immunology , Skin Diseases, Infectious/therapy , Immunologic Deficiency Syndromes/epidemiology , Immunologic Deficiency Syndromes/immunology , Immunologic Deficiency Syndromes/prevention & control , Immunologic Deficiency Syndromes/physiopathology , Candidiasis, Chronic Mucocutaneous/immunology , Candidiasis, Chronic Mucocutaneous/physiopathology , Skin Diseases, Infectious/prevention & control , Skin Diseases, Infectious/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...